Prestige Consumer Healthcare Inc. (NYSE:PBH) SVP Sells $810,273.45 in Stock

Prestige Consumer Healthcare Inc. (NYSE:PBH) SVP Mary Beth Fritz sold 9,885 shares of the company’s stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $81.97, for a total value of $810,273.45. Following the sale, the senior vice president now directly owns 18,835 shares of the company’s stock, valued at approximately $1,543,904.95. This represents a 34.42 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Prestige Consumer Healthcare Stock Down 0.5 %

NYSE:PBH opened at $82.36 on Friday. The firm has a market capitalization of $4.07 billion, a price-to-earnings ratio of 20.04, a PEG ratio of 2.32 and a beta of 0.47. Prestige Consumer Healthcare Inc. has a 1-year low of $56.61 and a 1-year high of $83.83. The company has a current ratio of 3.56, a quick ratio of 2.10 and a debt-to-equity ratio of 0.61. The business’s fifty day moving average price is $73.29 and its 200 day moving average price is $70.25.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings results on Thursday, November 7th. The company reported $1.09 earnings per share for the quarter, meeting the consensus estimate of $1.09. The firm had revenue of $283.79 million for the quarter, compared to analyst estimates of $282.09 million. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. Prestige Consumer Healthcare’s quarterly revenue was down .9% on a year-over-year basis. During the same period in the previous year, the firm earned $1.07 earnings per share. On average, sell-side analysts forecast that Prestige Consumer Healthcare Inc. will post 4.45 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Opal Wealth Advisors LLC acquired a new position in Prestige Consumer Healthcare in the 2nd quarter worth about $26,000. Quest Partners LLC increased its position in Prestige Consumer Healthcare by 2,826.7% in the 2nd quarter. Quest Partners LLC now owns 439 shares of the company’s stock worth $30,000 after purchasing an additional 424 shares during the last quarter. EverSource Wealth Advisors LLC increased its position in Prestige Consumer Healthcare by 80.6% in the 1st quarter. EverSource Wealth Advisors LLC now owns 466 shares of the company’s stock worth $33,000 after purchasing an additional 208 shares during the last quarter. Gladius Capital Management LP acquired a new position in Prestige Consumer Healthcare in the 2nd quarter worth about $35,000. Finally, Northwestern Mutual Wealth Management Co. increased its position in Prestige Consumer Healthcare by 562.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company’s stock worth $35,000 after purchasing an additional 433 shares during the last quarter. 99.95% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on PBH shares. DA Davidson reaffirmed a “buy” rating and set a $95.00 target price on shares of Prestige Consumer Healthcare in a report on Monday, November 11th. Jefferies Financial Group reaffirmed a “hold” rating and set a $76.00 target price (up from $70.00) on shares of Prestige Consumer Healthcare in a report on Tuesday, September 24th. One research analyst has rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $83.67.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.